| 000 | 01825 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516083636.0 | ||
| 264 | 0 | _c20120827 | |
| 008 | 201208s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/1471-2407-12-108 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBerger, Anne Katrin | |
| 245 | 0 | 0 |
_aA phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. _h[electronic resource] |
| 260 |
_bBMC cancer _cMar 2012 |
||
| 300 |
_a108 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCetuximab |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdiagnostic imaging |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorodeoxyglucose F18 _xpharmacokinetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPositron-Emission Tomography |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRadiopharmaceuticals _xpharmacokinetics |
| 700 | 1 | _avon Gall, Carl | |
| 700 | 1 | _aAbel, Ulrich | |
| 700 | 1 | _aDelorme, Stefan | |
| 700 | 1 | _aKloor, Matthias | |
| 700 | 1 | _aOse, Jennifer | |
| 700 | 1 | _aWeber, Tim Frederik | |
| 700 | 1 | _aStange, Annika | |
| 700 | 1 | _aHaag, Georg Martin | |
| 700 | 1 | _aHaberkorn, Uwe | |
| 700 | 1 | _aLordick, Florian | |
| 700 | 1 | _aJäger, Dirk | |
| 773 | 0 |
_tBMC cancer _gvol. 12 _gp. 108 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2407-12-108 _zAvailable from publisher's website |
| 999 |
_c21643471 _d21643471 |
||